A chlamydia vaccine has been trialed in humans for the first time   – and it was a success , with results put out inThe Lancet Infectious Diseasesshowing that it is safe and sparks an resistant response against the chlamydia - get bacteriumChlamydia trachomatis .

There is still a recollective way to go before it can be market to the public . succeeding trials will monitor its effectuality and establish the right dose , but news that it has made it through this first hurdle is promising .

" Given the wallop of the chlamydia epidemic on women ’s health , generative health , infant wellness through erect transmission , and increased susceptibility to other sexually impart disease , a ball-shaped unmet medical need exists for a vaccine against venereal chlamydia , " study author Peter Anderson from the Statens Serum Institut in Denmark said in astatement .

Two version of the vaccines and a placebo dig were tested in 35 women to determine its refuge and check that it can trigger an resistant answer . The first formulation hold back added CAF01 liposomes to boost cellular resistance , while the second included aluminum hydroxide , which is known to assist increase antibody production .

The vaccine was   deal with three injections ( on 24-hour interval 0 , 28 , and 112 ) and two intranasal boosts ( on daytime 126 and 140 ) . Thirty - two women received all five thrusting .

Both formulations caused an immune reply , but the one hold extra   CAF01 liposome produced 560 percent more antibodies . It also demonstrate an enhanced mucosal antibody profile and more consistent cell - mediated reaction profile – the first providing the first personal line of credit of defence against infection , the second associated with long - term immunity . Thus , it is this version of the vaccinum the researchers trust to take to the next level .

Globally , chlamydia is the most rough-cut sexually transmitted infection ( STI ) , calculate for roughly 131 million new cases every year . It can be transmitted through unprotected sex , even without penetration .

It is considered a " silent " disease because it so often does n’t present symptoms . Yet , if it is n’t by rights treated , it can conduce to infertility and other serious complications , let in ectopic pregnancy , spontaneous abortion , miscarriage , and preterm birth . It can also leave people more susceptible to other STIs , including gonorrhea and HIV .

The estimable intelligence is that it can be treated with antibiotics . Yet , despite this option ( and the widespread accessibility of examination ) , it is still a large public wellness job . This is where the researchers hope a vaccine will follow in useful . It could ply tenacious - terminal figure prophylactic aegis .

There is a long way to go before it can be reeled out on a national level   – the full-grown restriction at this stage is the lowly sample size , which may not expose rarer side effects to the vaccine or substantiate its potency at protecting against the disease .

" A vaccine for bar ofC trachomatisinfection would have enormous public health and economical wallop , "   Toni Darville from the University of North Carolina wrote in a linked gossip .

" Although clinical vaccine testing for chlamydia is in its infancy , this trial suggests optimism for the time to come . "